IM Cannabis Corp.

Medicinal Chemicals and Botanical Products company

📍 Canada NASDAQ IMCC Pharmaceuticals & Healthcare

Search companies

Key Metrics of IM Cannabis Corp.

Revenue₹359 Cr▲ 11.8% YoYFY 2025-26

EBITDA−₹53.5 Cr▼ 12.2% YoY

Net profit−₹77.1 Cr▼ 10.1% YoY

Net worth−₹24.5 Cr▼ 178.5% YoY

Market cap$1.2MIMCC · $0.72

Competitors10identified

About IM Cannabis Corp.

Sectors

Pharmaceuticals & HealthcareFormulations & Contract Manufacturing

Company details

Listed: Nasdaq: IMCC

Operational Areas of IM Cannabis Corp.

Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing

Company summary

Legal nameIM Cannabis Corp.

TickerIMCC

ExchangeNasdaq

CountryCanada

SEC CIK0001792030

Listed since—

Industry Medicinal Chemicals and Botanical Products

SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing

Website—

US market & SEC filings

IMCC · Nasdaq · SEC CIK 0001792030

Last price · 05 Nov 2026 $0.72 −1.04%

Market cap$1.2M

P/E—

Volume14,712

SectorHealth Care Medicinal Chemicals and Botanical Products

Country · IPOCanada

IMCC share price

Annual results (SEC EDGAR)

No annual results in SEC XBRL data for this company yet.

Premium

Financials, ratios and risk analysis

Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.

Vendor checks & payment capacity

Credit assessment · Manufacturing

Rating Methodology – Manufacturing Companies (Mar 2025) · Consolidated accounts · FY 2025-26

Indicative long-term—

Indicative short-term—

Score—

LiquidityPoor

DirectionStable

Ratios, pillar scores and the indicative rating are part of Premium.

Rating status

Default	No default on record
Issuer cooperation	Cooperating
Credit enhancement	None – standalone rating
Information on file	33% · missing: Debt obligations and repayment schedule, Capex / investment plans, Lender details, Auditor details, Shareholding pattern, Recent rating review (last 15 months)

Indicative assessment from public data using the published methodology factors; not a credit rating.

Registered office and contact

Registered office—

GSTIN—

Email—

Website—

Members / shareholders—

Directors and key people

Directors are read from the MGT-7 annual return and AOC-4 signatories.

Competitors of IM Cannabis Corp.

Competitors10identified

Countries1most in United States

Top competitors by location

Company	Description	Domain	Founded	Location
Eli Lilly and Company	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	lilly.com	—	United States
Johnson & Johnson	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	jjmt.com.tw	—	United States
Procter & Gamble	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	pg.com	—	United States
Merck & Co.	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	merck.com	—	United States
Amgen	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	amgen.com	1983	United States
Gilead Sciences	Part of Gilead Sciences.	gilead.com	1992	United States
Abbott Laboratories	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	abbott.com	—	United States
Pfizer	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	pfizer.com	—	United States
Marriott International	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	marriott.com.cn	—	United States
HCA Healthcare	Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare	hcahealthcare.com	2011	United States

Similar companies

Charges (secured borrowings)

0 registered charges. Lenders, amounts and dates are part of the premium plan.

Statutory auditors

Auditors are read from the AOC-4 auditor's report section.

Business activities and related parties

Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.

Filings

No filings on record yet.